Orexin 2 receptor antagonism sex-dependently improves sleep/wakefulness and cognitive performance in tau transgenic mice.
MK-1064
doxycycline
rTg4510
sleep
suvorexant
tau
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
25
07
2023
received:
08
02
2023
accepted:
01
08
2023
medline:
6
12
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
Tau pathology contributes to a bidirectional relationship between sleep disruption and neurodegenerative disease. Tau transgenic rTg4510 mice model tauopathy symptoms, including sleep/wake disturbances, which manifest as marked hyperarousal. This phenotype can be prevented by early transgene suppression; however, whether hyperarousal can be rescued after onset is unknown. Three 8-week experiments were conducted with wild-type and rTg4510 mice after age of onset of hyperarousal (4.5 months): (1) Tau transgene suppression with doxycycline (200 ppm); (2) inactive phase rapid eye movement (REM) sleep enhancement with the dual orexin receptor antagonist suvorexant (50 mg·kg Tau transgene suppression improved tauopathy and hippocampal-dependent spatial memory, but did not modify hyperarousal. Pharmacological rescue of REM sleep deficits did not improve spatial memory or tau pathology. In contrast, normalising hyperarousal by increasing both NREM and REM sleep via OX Pharmacologically reducing hyperarousal corrects tau-induced sleep/wake and cognitive deficits. Tauopathy causes sex-dependent disruptions of OX
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
Tau pathology contributes to a bidirectional relationship between sleep disruption and neurodegenerative disease. Tau transgenic rTg4510 mice model tauopathy symptoms, including sleep/wake disturbances, which manifest as marked hyperarousal. This phenotype can be prevented by early transgene suppression; however, whether hyperarousal can be rescued after onset is unknown.
EXPERIMENTAL APPROACH
METHODS
Three 8-week experiments were conducted with wild-type and rTg4510 mice after age of onset of hyperarousal (4.5 months): (1) Tau transgene suppression with doxycycline (200 ppm); (2) inactive phase rapid eye movement (REM) sleep enhancement with the dual orexin receptor antagonist suvorexant (50 mg·kg
KEY RESULTS
RESULTS
Tau transgene suppression improved tauopathy and hippocampal-dependent spatial memory, but did not modify hyperarousal. Pharmacological rescue of REM sleep deficits did not improve spatial memory or tau pathology. In contrast, normalising hyperarousal by increasing both NREM and REM sleep via OX
CONCLUSIONS AND IMPLICATIONS
CONCLUSIONS
Pharmacologically reducing hyperarousal corrects tau-induced sleep/wake and cognitive deficits. Tauopathy causes sex-dependent disruptions of OX
Substances chimiques
Orexins
0
Hypnotics and Sedatives
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87-106Subventions
Organisme : Alzheimer's Association
ID : 2016-NIRG396905
Pays : United States
Informations de copyright
© 2023 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Abbracchio, M. P., Alexander, W., Al-Hosaini, K., Bäck, M., Barnes, N. M., Bathgate, R., … Ye, R. D. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology, 178(Suppl 1), S27-S156.
Alexander, S. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Buneman, O. P., Cidlowski, J. A., Christopoulos, A., Davenport, A. P., Fabbro, D., Spedding, M., Striessnig, J., Davies, J. A., Ahlers-Dannen, K. E., … Zolghadri, Y. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Introduction and other protein targets. British Journal of Pharmacology, 178(Suppl 1), S1-S26. https://doi.org/10.1111/bph.15537
Alexander, S. P., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Aldrich, R. W., Attali, B., Baggetta, A. M., Becirovic, E., Biel, M., Bill, R. M., Catterall, W. A., … Zhu, M. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. British Journal of Pharmacology, 178(Suppl 1), S157-S245.
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of pharmacology. British Journal of Pharmacology, 175, 407-411. https://doi.org/10.1111/bph.14112
Allocca, G., Ma, S., Martelli, D., Cerri, M., Del Vecchio, F., Bastianini, S., Zoccoli, G., Amici, R., Morairty, S. R., Aulsebrook, A. E., Blackburn, S., Lesku, J. A., Rattenborg, N. C., Vyssotski, A. L., Wams, E., Porcheret, K., Wulff, K., Foster, R., Chan, J. K. M., … Gundlach, A. L. (2019). Validation of 'Somnivore', a machine learning algorithm for automated scoring and analysis of polysomnography data. Frontiers in Neuroscience, 13, 207. https://doi.org/10.3389/fnins.2019.00207
Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012). Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron, 74, 467-474. https://doi.org/10.1016/j.neuron.2012.03.023
Barnes, C. A. (1979). Memory deficits associated with senescence: A neurophysiological and behavioral study in the rat. Journal of Comparative and Physiological Psychology, 93, 74-104. https://doi.org/10.1037/h0077579
Baumann, K., Mandelkow, E. M., Biernat, J., Piwnica-Worms, H., & Mandelkow, E. (1993). Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Letters, 336, 417-424. https://doi.org/10.1016/0014-5793(93)80849-P
Bero, A. W., Yan, P., Roh, J. H., Cirrito, J. R., Stewart, F. R., Raichle, M. E., Lee, J. M., & Holtzman, D. M. (2011). Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nature Neuroscience, 14, 750-756. https://doi.org/10.1038/nn.2801
Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Fendt, M., Gee, C. E., Jacobson, L. H., Laue, G., Ofner, S., Chaudhari, V., Badiger, S., Pandit, C., Wagner, J., & Hoyer, D. (2013). Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. Journal of Medicinal Chemistry, 56, 7590-7607. https://doi.org/10.1021/jm4007627
Binder, S., Berg, K., Gasca, F., Lafon, B., Parra, L. C., Born, J., & Marshall, L. (2014). Transcranial slow oscillation stimulation during sleep enhances memory consolidation in rats. Brain Stimulation, 7, 508-515. https://doi.org/10.1016/j.brs.2014.03.001
Blackmore, T., Meftah, S., Murray, T. K., Craig, P. J., Blockeel, A., Phillips, K., Eastwood, B., O'Neill, M. J., Marston, H., Ahmed, Z., Gilmour, G., & Gastambide, F. (2017). Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy. Alzheimer's Research & Therapy, 9, 77. https://doi.org/10.1186/s13195-017-0306-2
Bonanni, E., Maestri, M., Tognoni, G., Fabbrini, M., Nucciarone, B., Manca, M. L., Gori, S., Iudice, A., & Murri, L. (2005). Daytime sleepiness in mild and moderate Alzheimer's disease and its relationship with cognitive impairment. Journal of Sleep Research, 14, 311-317. https://doi.org/10.1111/j.1365-2869.2005.00462.x
Boyce, R., Glasgow, S. D., Williams, S., & Adamantidis, A. (2016). Causal evidence for the role of REM sleep theta rhythm in contextual memory consolidation. Science, 352, 812-816. https://doi.org/10.1126/science.aad5252
Braak, H., & Del Tredici, K. (2011). The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathologica, 121, 171-181. https://doi.org/10.1007/s00401-010-0789-4
Braak, H., & Del Tredici, K. (2015). The preclinical phase of the pathological process underlying sporadic Alzheimer's disease. Brain, 138, 2814-2833. https://doi.org/10.1093/brain/awv236
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years. Journal of Neuropathology and Experimental Neurology, 70, 960-969. https://doi.org/10.1097/NEN.0b013e318232a379
Chauvette, S., Seigneur, J., & Timofeev, I. (2012). Sleep oscillations in the thalamocortical system induce long-term neuronal plasticity. Neuron, 75, 1105-1113. https://doi.org/10.1016/j.neuron.2012.08.034
Cirrito, J. R., Kang, J. E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S., & Holtzman, D. M. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron, 58, 42-51. https://doi.org/10.1016/j.neuron.2008.02.003
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron, 48, 913-922. https://doi.org/10.1016/j.neuron.2005.10.028
Clark, J. W., Brian, M. L., Drummond, S. P. A., Hoyer, D., & Jacobson, L. H. (2020). Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Medicine Reviews, 53, 101332. https://doi.org/10.1016/j.smrv.2020.101332
Cox, C. D., Breslin, M. J., Whitman, D. B., Schreier, J. D., McGaughey, G. B., Bogusky, M. J., Roecker, A. J., Mercer, S. P., Bednar, R. A., Lemaire, W., Bruno, J. G., Reiss, D. R., Harrell, C. M., Murphy, K. L., Garson, S. L., Doran, S. M., Prueksaritanont, T., Anderson, W. B., Tang, C., … Coleman, P. J. (2010). Discovery of the dual orexin receptor antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. Journal of Medicinal Chemistry, 53, 5320-5332. https://doi.org/10.1021/jm100541c
Cullell, N., Carcel-Marquez, J., Gallego-Fabrega, C., Muino, E., Llucia-Carol, L., Lledos, M., Amaut, K. E. U., Krupinski, J., & Fernández-Cadenas, I. (2021). Sleep/wake cycle alterations as a cause of neurodegenerative diseases: A Mendelian randomization study. Neurobiology of Aging, 106, 320 e321-320 e312.
Curtis, M. J., Alexander, S. P. H., Cirino, G., George, C. H., Kendall, D. A., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Patel, H. H., Sobey, C. G., Stanford, S. C., Stanley, P., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ahluwalia, A. (2022). Planning experiments: Updated guidance on experimental design and analysis and their reporting III. British Journal of Pharmacology, 179(15), 3907-3913. Portico. https://doi.org/10.1111/bph.15868
Despres, C., Byrne, C., Qi, H., Cantrelle, F. X., Huvent, I., Chambraud, B., Baulieu, E. E., Jacquot, Y., Landrieu, I., Lippens, G., & Smet-Nocca, C. (2017). Identification of the tau phosphorylation pattern that drives its aggregation. Proceedings of the National Academy of Sciences of the United States of America, 114, 9080-9085. https://doi.org/10.1073/pnas.1708448114
Diekelmann, S., & Born, J. (2010). The memory function of sleep. Nature Reviews. Neuroscience, 11, 114-126. https://doi.org/10.1038/nrn2762
Donnelly, K., Bracchi, R., Hewitt, J., Routledge, P. A., & Carter, B. (2017). Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS ONE, 12, e0174730. https://doi.org/10.1371/journal.pone.0174730
Dugovic, C., Shelton, J. E., Yun, S., Bonaventure, P., Shireman, B. T., & Lovenberg, T. W. (2014). Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Frontiers in Neuroscience, 8, 28.
Gotter, A. L., Forman, M. S., Harrell, C. M., Stevens, J., Svetnik, V., Yee, K. L., Li, X., Roecker, A. J., Fox, S. V., Tannenbaum, P. L., Garson, S. L., Lepeleire, I. D., Calder, N., Rosen, L., Struyk, A., Coleman, P. J., Herring, W. J., Renger, J. J., & Winrow, C. J. (2016). Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man. Scientific Reports, 6, 27147. https://doi.org/10.1038/srep27147
Gotter, A. L., Winrow, C. J., Brunner, J., Garson, S. L., Fox, S. V., Binns, J., Harrell, C. M., Cui, D., Yee, K. L., Stiteler, M., Stevens, J., Savitz, A., Tannenbaum, P. L., Tye, S. J., McDonald, T., Yao, L., Kuduk, S. D., Uslaner, J., Coleman, P. J., & Renger, J. J. (2013). The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neuroscience, 14, 90. https://doi.org/10.1186/1471-2202-14-90
Grafe, L. A., & Bhatnagar, S. (2020). The contribution of orexins to sex differences in the stress response. Brain Research, 1731, 145893. https://doi.org/10.1016/j.brainres.2018.07.026
Hall-Porter, J. M., Schweitzer, P. K., Eisenstein, R. D., Ahmed, H. A., & Walsh, J. K. (2014). The effect of two benzodiazepine receptor agonist hypnotics on sleep-dependent memory consolidation. Journal of Clinical Sleep Medicine, 10, 27-34. https://doi.org/10.5664/jcsm.3352
Herring, W. J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J., Lines, C., & Michelson, D. (2020). Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: A randomized trial. Alzheimers Dement, 16, 541-551. https://doi.org/10.1002/alz.12035
Holth, J. K., Fritschi, S. K., Wang, C., Pedersen, N. P., Cirrito, J. R., Mahan, T. E., Finn, M. B., Manis, M., Geerling, J. C., Fuller, P. M., Lucey, B. P., & Holtzman, D. M. (2019). The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science, 363, 880-884. https://doi.org/10.1126/science.aav2546
Holth, J. K., Mahan, T. E., Robinson, G. O., Rocha, A., & Holtzman, D. M. (2017). Altered sleep and EEG power in the P301S tau transgenic mouse model. Annals of Clinical Translational Neurology, 4, 180-190. https://doi.org/10.1002/acn3.390
Holton, C. M., Hanley, N., Shanks, E., Oxley, P., McCarthy, A., Eastwood, B. J., Murray, T. K., Nickerson, A., & Wafford, K. A. (2020). Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration. Alzheimer's Research & Therapy, 12, 84. https://doi.org/10.1186/s13195-020-00651-0
Hoyer, D., Allen, A., & Jacobson, L. H. (2019). Hypnotics with novel modes of action. British Journal of Clinical Pharmacology, 86, 244-249. https://doi.org/10.1111/bcp.14180
Hoyer, D., Durst, T., Fendt, M., Jacobson, L. H., Betschart, C., Hintermann, S., Behnke, D., Cotesta, S., Laue, G., Ofner, S., Legangneux, E., & Gee, C. E. (2013). Distinct effects of IPSU and suvorexant on mouse sleep architecture. Frontiers in Neuroscience, 7, 235.
Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., & Lee, V. M. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. The Journal of Neuroscience, 33, 1024-1037. https://doi.org/10.1523/JNEUROSCI.2642-12.2013
Iliff, J. J., Chen, M. J., Plog, B. A., Zeppenfeld, D. M., Soltero, M., Yang, L., Singh, I., Deane, R., & Nedergaard, M. (2014). Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. The Journal of Neuroscience, 34, 16180-16193. https://doi.org/10.1523/JNEUROSCI.3020-14.2014
Iliff, J. J., Lee, H., Yu, M., Feng, T., Logan, J., Nedergaard, M., & Benveniste, H. (2013). Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. The Journal of Clinical Investigation, 123, 1299-1309. https://doi.org/10.1172/JCI67677
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., Nagelhus, E. A., & Nedergaard, M. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Science Translational Medicine, 4, 147ra111.
Jacobson, L. H., Chen, S., Mir, S., & Hoyer, D. (2017). Orexin OX2 receptor antagonists as sleep aids. Current Topics in Behavioral Neurosciences, 33, 105-136. https://doi.org/10.1007/7854_2016_47
Jacobson, L. H., Hoyer, D., & de Lecea, L. (2022). Hypocretins (orexins): The ultimate translational neuropeptides. Journal of Internal Medicine, 291, 533-556. https://doi.org/10.1111/joim.13406
Ju, Y. E., Lucey, B. P., & Holtzman, D. M. (2014). Sleep and Alzheimer disease pathology-A bidirectional relationship. Nature Reviews. Neurology, 10, 115-119. https://doi.org/10.1038/nrneurol.2013.269
Jul, P., Volbracht, C., de Jong, I. E., Helboe, L., Elvang, A. B., & Pedersen, J. T. (2016). Hyperactivity with Agitative-like behavior in a mouse Tauopathy model. Journal of Alzheimer's Disease, 49, 783-795. https://doi.org/10.3233/JAD-150292
Kang, J. E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., Fujiki, N., Nishino, S., & Holtzman, D. M. (2009). Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science, 326, 1005-1007. https://doi.org/10.1126/science.1180962
Keenan, R. J., Daykin, H., Chu, J., Cornthwaite-Duncan, L., Allocca, G., Hoyer, D., & Jacobson, L. H. (2022). Differential sleep/wake response and sex differences following acute suvorexant, MK-1064 and zolpidem administration in the rTg4510 mouse model of tauopathy. British Journal of Pharmacology, 179, 3403-3417. https://doi.org/10.1111/bph.15813
Keenan, R. J., Oberrauch, S., Bron, R., Nowell, C. J., Challis, L. M., Hoyer, D., & Jacobson, L. H. (2021). Decreased orexin receptor 1 mRNA expression in the locus Coeruleus in both tau transgenic rTg4510 and tau knockout mice and accompanying ascending arousal system tau invasion in rTg4510. Journal of Alzheimer's Disease, 79, 693-708. https://doi.org/10.3233/JAD-201177
Koss, D. J., Robinson, L., Drever, B. D., Plucinska, K., Stoppelkamp, S., Veselcic, P., Riedel, G., & Platt, B. (2016). Mutant tau knock-in mice display frontotemporal dementia relevant behaviour and histopathology. Neurobiology of Disease, 91, 105-123. https://doi.org/10.1016/j.nbd.2016.03.002
Laws, K. R., Irvine, K., & Gale, T. M. (2018). Sex differences in Alzheimer's disease. Current Opinion in Psychiatry, 31(2), 133-139. https://doi.org/10.1097/yco.0000000000000401
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P. H., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611-3616. Portico. https://doi.org/10.1111/bph.15178
Lim, M. M., Gerstner, J. R., & Holtzman, D. M. (2014). The sleep-wake cycle and Alzheimer's disease: What do we know? Neurodegenerative Disease Management, 4, 351-362. https://doi.org/10.2217/nmt.14.33
Lopera, F., Marino, C., Chandrahas, A. S., O’Hare, M., Villalba-Moreno, N. D., Aguillon, D., Baena, A., Sanchez, J. S., Vila-Castelar, C., Ramirez Gomez, L., Chmielewska, N., Oliveira, G. M., Littau, J. L., Hartmann, K., Park, K., Krasemann, S., Glatzel, M., Schoemaker, D., Gonzalez-Buendia, L., … Quiroz, Y. T. (2023). Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man. Nature Medicine, 29(5), 1243-1252. https://doi.org/10.1038/s41591-023-02318-3
Mandelkow, E. M., Drewes, G., Biernat, J., Gustke, N., Van Lint, J., Vandenheede, J. R., & Mandelkow, E. (1992). Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Letters, 314, 315-321. https://doi.org/10.1016/0014-5793(92)81496-9
Mang, G. M., Durst, T., Burki, H., Imobersteg, S., Abramowski, D., Schuepbach, E., Hoyer, D., Fendt, M., & Gee, C. E. (2012). The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors. Sleep, 35, 1625-1635. https://doi.org/10.5665/sleep.2232
Marshall, L., Helgadottir, H., Molle, M., & Born, J. (2006). Boosting slow oscillations during sleep potentiates memory. Nature, 444, 610-613. https://doi.org/10.1038/nature05278
Mattila, M. J., Vanakoski, J., Kalska, H., & Seppala, T. (1998). Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacology Biochemistry and Behavior, 59, 917-923. https://doi.org/10.1016/S0091-3057(97)00506-6
Mieda, M., Hasegawa, E., Kisanuki, Y. Y., Sinton, C. M., Yanagisawa, M., & Sakurai, T. (2011). Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. The Journal of Neuroscience, 31, 6518-6526. https://doi.org/10.1523/JNEUROSCI.6506-10.2011
Mintzer, M. Z., & Griffiths, R. R. (1999). Selective effects of zolpidem on human memory functions. Journal of Psychopharmacology, 13, 18-31. https://doi.org/10.1177/026988119901300103
Morairty, S. R., Revel, F. G., Malherbe, P., Moreau, J. L., Valladao, D., Wettstein, J. G., Kilduff, T. S., & Borroni, E. (2012). Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone. PLoS ONE, 7, e39131. https://doi.org/10.1371/journal.pone.0039131
Morairty, S. R., Wilk, A. J., Lincoln, W. U., Neylan, T. C., & Kilduff, T. S. (2014). The hypocretin/orexin antagonist almorexant promotes sleep without impairment of performance in rats. Frontiers in Neuroscience, 8, 3.
Moran, M., Lynch, C. A., Walsh, C., Coen, R., Coakley, D., & Lawlor, B. A. (2005). Sleep disturbance in mild to moderate Alzheimer's disease. Sleep Medicine, 6, 347-352. https://doi.org/10.1016/j.sleep.2004.12.005
Otmani, S., Demazieres, A., Staner, C., Jacob, N., Nir, T., Zisapel, N., & Staner, L. (2008). Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Human Psychopharmacology, 23, 693-705. https://doi.org/10.1002/hup.980
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. British Journal of Pharmacology, 177(16), 3617-3624. Portico. https://doi.org/10.1111/bph.15193
Podcasy, J. L., & Epperson, C. N. (2016). Considering sex and gender in Alzheimer disease and other dementias. Dialogues in Clinical Neuroscience, 18(4), 437-446. https://doi.org/10.31887/dcns.2016.18.4/cepperson
Pooler, A. M., Phillips, E. C., Lau, D. H., Noble, W., & Hanger, D. P. (2013). Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Reports, 14, 389-394. https://doi.org/10.1038/embor.2013.15
Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., Hutton, M., & Ashe, K. H. (2005). Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). The Journal of Neuroscience, 25, 10637-10647. https://doi.org/10.1523/JNEUROSCI.3279-05.2005
Roecker, A. J., Mercer, S. P., Schreier, J. D., Cox, C. D., Fraley, M. E., Steen, J. T., Lemaire, W., Bruno, J. G., Harrell, C. M., Garson, S. L., Gotter, A. L., Fox, S. V., Stevens, J., Tannenbaum, P. L., Prueksaritanont, T., Cabalu, T. D., Cui, D., Stellabott, J., Hartman, G. D., … Coleman, P. J. (2014). Discovery of 5″-chloro-N-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3″-terpyridine-3′-carbo xamide (MK-1064): A selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia. ChemMedChem, 9, 311-322. https://doi.org/10.1002/cmdc.201300447
Roh, J. H., Huang, Y., Bero, A. W., Kasten, T., Stewart, F. R., Bateman, R. J., & Holtzman, D. M. (2012). Disruption of the sleep-wake cycle and diurnal fluctuation of beta-amyloid in mice with Alzheimer's disease pathology. Science Translational Medicine, 4, 150ra122.
Roh, J. H., Jiang, H., Finn, M. B., Stewart, F. R., Mahan, T. E., Cirrito, J. R., Heda, A., Snider, B. J., Li, M., Yanagisawa, M., de Lecea, L., & Holtzman, D. M. (2014). Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. The Journal of Experimental Medicine, 211, 2487-2496. https://doi.org/10.1084/jem.20141788
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G. Q., Palop, J. J., & Mucke, L. (2012). Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proceedings of the National Academy of Sciences of the United States of America, 109, E2895-E2903. https://doi.org/10.1073/pnas.1121081109
Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., & Ashe, K. H. (2005). Tau suppression in a neurodegenerative mouse model improves memory function. Science, 309, 476-481. https://doi.org/10.1126/science.1113694
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., Tinevez, J. Y., White, D. J., Hartenstein, V., Eliceiri, K., Tomancak, P., & Cardona, A. (2012). Fiji: An open-source platform for biological-image analysis. Nature Methods, 9, 676-682. https://doi.org/10.1038/nmeth.2019
Schwartz, M. D., Nguyen, A. T., Warrier, D. R., Palmerston, J. B., Thomas, A. M., Morairty, S. R., Neylan, T. C., & Kilduff, T. S. (2016). Locus Coeruleus and Tuberomammillary nuclei ablations attenuate Hypocretin/orexin antagonist-mediated REM sleep. eNeuro, 3, 1-17. https://doi.org/10.1523/ENEURO.0018-16.2016
Seshadri, S., Wolf, P. A., Beiser, A., Au, R., McNulty, K., White, R., & D’Agostino, R. B. (1997). Lifetime risk of dementia and Alzheimer's disease: The impact of mortality on risk estimates in the Framingham Study. Neurology, 49(6), 1498-1504. https://doi.org/10.1212/wnl.49.6.1498
Song, L., Lu, S. X., Ouyang, X., Melchor, J., Lee, J., Terracina, G., Wang, X., Hyde, L., Hess, J. F., Parker, E. M., & Zhang, L. (2015). Analysis of tau post-translational modifications in rTg4510 mice, a model of tau pathology. Molecular Neurodegeneration, 10, 14. https://doi.org/10.1186/s13024-015-0011-1
Stratmann, K., Heinsen, H., Korf, H. W., Del Turco, D., Ghebremedhin, E., Seidel, K., Bouzrou, M., Grinberg, L. T., Bohl, J., Wharton, S. B., den Dunnen, W., & Rüb, U. (2016). Precortical phase of Alzheimer's disease (AD)-related tau cytoskeletal pathology. Brain Pathology, 26, 371-386. https://doi.org/10.1111/bpa.12289
Tabuchi, M., Lone, S. R., Liu, S., Liu, Q., Zhang, J., Spira, A. P., & Wu, M. N. (2015). Sleep interacts with abeta to modulate intrinsic neuronal excitability. Current Biology, 25, 702-712. https://doi.org/10.1016/j.cub.2015.01.016
Tournier, J. D., Smith, R., Raffelt, D., Tabbara, R., Dhollander, T., Pietsch, M., Christiaens, D., Jeurissen, B., Yeh, C. H., & Connelly, A. (2019). MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. NeuroImage, 202, 116137. https://doi.org/10.1016/j.neuroimage.2019.116137
Treves, N., Perlman, A., Kolenberg Geron, L., Asaly, A., & Matok, I. (2018). Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age and Ageing, 47, 201-208. https://doi.org/10.1093/ageing/afx167
Verster, J. C., Volkerts, E. R., Schreuder, A. H., Eijken, E. J., van Heuckelum, J. H., Veldhuijzen, D. S., Verbaten, M. N., Paty, I., Darwish, M., Danjou, P., & Patat, A. (2002). Residual effects of middle-of-the-night administration of zaleplon and zolpidem on driving ability, memory functions, and psychomotor performance. Journal of Clinical Psychopharmacology, 22, 576-583. https://doi.org/10.1097/00004714-200212000-00007
Wang, C., & Holtzman, D. M. (2020). Bidirectional relationship between sleep and Alzheimer's disease: Role of amyloid, tau, and other factors. Neuropsychopharmacology, 45, 104-120. https://doi.org/10.1038/s41386-019-0478-5
Wang, X., Smith, K., Pearson, M., Hughes, A., Cosden, M. L., Marcus, J., Hess, J. F., Savage, M. J., Rosahl, T., Smith, S. M., Schachter, J. B., & Uslaner, J. M. (2018). Early intervention of tau pathology prevents behavioral changes in the rTg4510 mouse model of tauopathy. PLoS ONE, 13, e0195486. https://doi.org/10.1371/journal.pone.0195486
Wang, Y., Balaji, V., Kaniyappan, S., Kruger, L., Irsen, S., Tepper, K., Chandupatla, R., Maetzler, W., Schneider, A., Mandelkow, E., & Mandelkow, E. M. (2017). The release and trans-synaptic transmission of tau via exosomes. Molecular Neurodegeneration, 12, 5. https://doi.org/10.1186/s13024-016-0143-y
Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rilett, K., Sanders, D. W., Cook, C., Fu, H., Boonen, R. A. C. M., Herman, M., Nahmani, E., Emrani, S., Figueroa, Y. H., Diamond, M. I., Clelland, C. L., Wray, S., & Duff, K. E. (2016). Neuronal activity enhances tau propagation and tau pathology in vivo. Nature Neuroscience, 19, 1085-1092. https://doi.org/10.1038/nn.4328
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O'Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., Takano, T., Deane, R., & Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342, 373-377. https://doi.org/10.1126/science.1241224
Yamada, K., Holth, J. K., Liao, F., Stewart, F. R., Mahan, T. E., Jiang, H., Cirrito, J. R., Patel, T. K., Hochgräfe, K., Mandelkow, E. M., & Holtzman, D. M. (2014). Neuronal activity regulates extracellular tau in vivo. The Journal of Experimental Medicine, 211, 387-393. https://doi.org/10.1084/jem.20131685
Yue, M., Hanna, A., Wilson, J., Roder, H., & Janus, C. (2011). Sex difference in pathology and memory decline in rTg4510 mouse model of tauopathy. Neurobiology of Aging, 32, 590-603. https://doi.org/10.1016/j.neurobiolaging.2009.04.006
Yushkevich, P. A., Piven, J., Hazlett, H. C., Smith, R. G., Ho, S., Gee, J. C., & Gerig, G. (2006). User-guided 3D active contour segmentation of anatomical structures: Significantly improved efficiency and reliability. NeuroImage, 31, 1116-1128. https://doi.org/10.1016/j.neuroimage.2006.01.015
Zhou, F., Yan, X. D., Wang, C., He, Y. X., Li, Y. Y., Zhang, J., Wang, Z. J., Cai, H. Y., Qi, J. S., & Wu, M. N. (2020). Suvorexant ameliorates cognitive impairments and pathology in APP/PS1 transgenic mice. Neurobiology of Aging, 91, 66-75. https://doi.org/10.1016/j.neurobiolaging.2020.02.020
Zhu, Y., Zhan, G., Fenik, P., Brandes, M., Bell, P., Francois, N., Shulman, K., & Veasey, S. (2018). Chronic sleep disruption advances the temporal progression of Tauopathy in P301S mutant mice. The Journal of Neuroscience, 38, 10255-10270. https://doi.org/10.1523/JNEUROSCI.0275-18.2018